INTRODUCTION {#s1}
============

Over the past 2 decades, amphetamine-type stimulants (ATS) and ketamine have become increasingly prevalent in China \[[@R1]-[@R3]\]. According to China's Annual Report on Drug Control issued by the Narcotic Control Commission, the number of illicit drug users, who had been registered in the Department of Public Security, was 24.75 million in 2013; among them, synthetic drug users accounted for almost a half \[[@R4]\]. ATS and/or ketamine dependence and/or abuse is of particularly clinical concern, because of its associated psychotic symptoms \[[@R5]-[@R8]\]. Recent studies reported that, 26-46% of individuals who use ATS or ketamine experienced psychotic symptoms \[[@R9]\], which occurred more frequently than cocaine \[[@R10]\] and cannabis users \[[@R11]\].

Previous research indicates that chronic/heavy ATS or ketamine use may induce psychotic symptoms resembling positive symptoms of schizophrenia, such as suspiciousness, delusions of persecution and hallucinations \[[@R12], [@R13]\], perceptual changes, ideas of reference, thought disorder \[[@R14]-[@R16]\] , and some negative symptoms like blunted affect and diminished spontaneity \[[@R17], [@R18]\]. In China, one recent study reported more psychiatric symptoms and more severe drug-induced schizophrenia-like symptoms in chronic methamphetamine users than chronic ketamine users \[[@R19]\]. However, findings from this study may have limited generality, because ATS and ketamine are often used together in China, which may lead to additional or more severe psychotic symptoms \[[@R20]\]. For example, one study conducted in the United States reported that ATS and ketamine taken together resulted in additive effects, leading to thought disorder, arousal, euphoria and less-than-additive effects on psychosis \[[@R21]\]. To the best of our knowledge, few clinical studies had investigated the synergistic effect of dual use of ATS and ketamine on drug-induced psychotic symptoms in China. Given the increasing number of users of ATS and ketamine in China, it is important to understand the effects of combination use on psychotic symptoms of synthetic drug users.

The current study examined psychotic symptoms among adult inpatients who diagnosed with ATS and/or Ketamine induced psychosis. To determine the synthetic effects of combined ATS and ketamine use on users' psychiatric symptom profiles, we compared psychotic symptoms between patients who use both ATS and ketamine, and ATS or ketamine alone.

RESULTS {#s2}
=======

Basic characteristics of study participants {#s2_1}
-------------------------------------------

The majority of participants in our sample were young males with low education levels and unstable jobs. Detailed demographic and drug use characteristics for the 4 groups were shown in Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"}. There were no statistically significant differences on demographic and drug use characteristics between the ATS-mainly group and the ATS-only group, and the ketamine-mainly group and the ketamine-only group.

###### Demographic characteristics of study participants

  Variables            AST mainly (*n*=150)   ATS only (*n*=125)   *P*       K mainly (*n*=62)   K only (*n*=38)   *P*
  -------------------- ---------------------- -------------------- --------- ------------------- ----------------- -------
  Gender                                                                                                           
  Male                 125(83.3)              99 (79.2)            0.380     49(79.0)            30 (78.9)         0.591
  Female               25(16.7)               26 (20.8)                      13(21.0)            8 (21.1)          
  Age                                                                                                              
  ≤20                  5(3.3)                 2 (1.6)              0.219     3(4.8)              3 (7.9)           0.487
  21-30                76(50.7)               68 (54.4)                      33(53.2)            19 (50.0)         
  1-40                 51(34.0)               48 (38.4)                      20(32.3)            15 (39.5)         
  \>41                 18(12.0)               7 (5.6)                        6(9.7)              1 (2.6)           
  Marital Status                                                                                                   
  Single               68(45.3)               48 (38.4)            0.474     28(45.2)            21 (55.3)         0.107
  Married              64(42.7)               62 (49.6)                      24(38.7)            16 (42.1)         
  Divorced/Separated   18(12.0)               15 (12.0)                      10(16.1)            1 (2.6)           
  Education levels                                                                                                 
  Less 9 years         126(84.0)              94 (75.2)            0.138     52(83.9)            28 (73.7)         0.206
  High school          20(13.3)               23 (18.4)                      5(8.1)              7 (18.4)          
  College or above     4(2.7)                 8 (6.4)                        5(8.1)              3 (7.9)           
  Occupation                                                                                                       
  Unemployed           52(34.7)               17 (13.6)            \<0.001   19(30.6)            6 (15.8)          0.409
  Businessman          37(24.7)               41 (32.8)                      12(19.4)            10 (26.3)         
  Entertainment        11(7.3)                6 (4.8)                        6(9.7)              4 (10.5)          
  Migrant worker       50(33.3)               61 (48.8)                      25(40.3)            18 (47.4)         
  Urine test                                                                                                       
  ATS (+)              114                    86                   \-\--     3                   0                 \--
  ATS (-)              36                     39                             59                  0                 
  K (+)                40                     0                              58                  17                
  K (-)                110                    0                              4                   21                

Note: Values are given as number (%).

###### Drug use characteristics of study participants

  Variables              ATS mainly (*n*=150)   ATS only (*n*=150)   *P*     K mainly (*n*=62)   K only (*n*=38)   *P*
  ---------------------- ---------------------- -------------------- ------- ------------------- ----------------- -------
  ATS                                                                                                              
  Age of first use       20.32±6.12             17.28±5.44           0.185   21.15±7.69                            
  Range, yrs             15-42                  13-36                        17-40                                 
  Duration, months       44.20±13.27            42.32±11.88          0.327   18.41±4.72                            
  Range, months          12-96                  6-102                        9-36                                  
  Frequency, per month   16.11±6.44             17.12±4.10           0.43    3.78±2.98                             
  Range, per month       10-28                  8-30                         1-6                                   
  Single dose, g         0.45±0.43              0.47±0.32            0.114   0.28±0.34                             
  Range, g               0.1-0.2                0.1-1.0                      0.05-0.3                              
  Ketamine                                                                                                         
  Age of first use       18.13±8.66                                          20.13±8.19          21.67±10.13       0.560
  Range,yrs              12-36                                               16-45               18-51             
  Duration,months        52.35±15.40                                         62.92±18.86         65.06±17.38       0.384
  Range,months           30-108                                              42-120              38-114            
  Frequency,per month    3.21±2.14                                           10.19±4.87          10.42±4.13        0.782
  Range,per month        1-6                                                 4-14                2-16              
  Single dose,g          0.35±0.32                                           0.42±0.34           0.45±0.42         0.445
  Range,g                0.1-0.3                                             0.2-0.6             0.1-0.8           

Note: Values given as mean and standard deviations.

The association between combined use of ATS and ketamine and psychotic symptoms {#s2_2}
-------------------------------------------------------------------------------

As displayed in Table [3](#T3){ref-type="table"}, ATS-mainly group had more anxiety/depression and anergia symptoms than ATS-only group (*p* \< 0.001), and ketamine-mainly group had more thinking-disorder, activity and hostility-suspicion symptoms than ketamine-only group (*P* ≤ 0.001). Overall, while there was no significant difference in BPRS total score between ATS-mainly and ATS-only groups (*P* = 0.217), ketamine-mainly group scored significantly higher on BPRS than ketamine-only group (*P* ≤ 0.001).

###### Comparisons of BPRS scores between subjects of different drug use characteristics

  BPRS                  ATS mainly   ATS only     t       *P*       K mainly    K only       t       *P*
  --------------------- ------------ ------------ ------- --------- ----------- ------------ ------- ---------
  Anxiety/depression    1.93±0.84    1.53±0.35    4.975   \<0.001   3.18±0.76   2.91±0.49    1.953   0.053
  Anergia               1.30±0.30    1.06±0.11    8.48    \<0.001   1.85±0.55   1.91±0.61    0.508   0.613
  Thinking-disorder     3.00±0.80    3.15±0.71    1.629   0.105     2.16±0.62   1.74±0.57    3.389   0.001
  Activity              2.97±0.66    3.06±0.68    1.111   0.267     2.40±0.82   1.61±0.32    5.671   \<0.001
  Hostility-suspicion   4.62±0.82    4.81±0.95    1.78    0.076     3.51±1.05   3.02±0.79    2.477   0.015
  Total score           47.60±8.14   46.50±6.24   1.238   0.217     46.52±5.9   40.13±7.68   4.679   \<0.001

DISCUSSION {#s3}
==========

In this study, we found that the anxiety/depression and anergia symptom scores of ATS-mainly group were significantly higher than ATS-only group, while the total BPRS score, thought disorder, activity score and hostility-suspicion symptoms of ketamine-mainly group were more prevalent than ketamine-only group. These results suggest that the psychotic symptoms induced by the combined use of ATS and ketamine are more severe than those induced by ATS/ ketamine alone. Our data indicate that ketamine use may exacerbate depression and anergia symptoms of ATS users and, ATS may exacerbate the thinking-disorders, activity and hostility-suspicion symptoms of ketamine users.

Consistent with 2 earlier studies \[[@R21], [@R22]\], our findings suggest that the psychotic symptoms caused by the combination of ATS and ketamine are not the supra-additive or even fully additive psychotic effects of either ATS or ketamine alone. Previous studies have reported that the noncompetitive glutamate N-methyl-D-aspartate (NMDA) antagonist could regulate the dopamine release in nucleus accumbens \[[@R23]-[@R25]\]. Based on the dopamine hypothesis on mechanisms of psychotic symptoms of schizophrenia \[[@R26], [@R27]\] , it seems that ATS and ketamine may share similar psychopathological mechanism, which results in a ceiling effect on psychotic symptoms. However, findings from our study were a little different from this hypothesis, that is, we found that ATS-mainly group had significantly more symptoms of depression and anergia than the ATS-only, whereas ketamine-mainly group had significant more symptoms of thought disorders and activity and hostility-suspicion. We, therefore, speculated that ATS and ketamine might still have different psychopathological mechanisms. These results were confirmed by our previous study, in which we found the ATS and ketamine user present with different profile of psychiatric symptoms \[[@R20]\]. It is possible that the interaction of ATS and ketamine, at the neurological level, affecting NMDA glutamate receptor and monoaminergic systems in the human brain, may antagonize some effects of the other drugs \[[@R28], [@R29]\] , or the dopaminergic response induced by ketamine treatment, in general, acts as a compensatory mechanism \[[@R30]-[@R33]\], which exaggerates or attenuates the emergence of psychotic symptoms. Further experimental research is needed to understand the potential mechanism of combined ATS and ketamine on neural system.

There are some methodological limitations in this study. Firstly, this was an observational study, and we were not able to control all possible confounding factors such as the dosage of drugs that influence psychotic symptoms. Secondly, our study participants were inpatients from a large psychiatric specialty hospital. Some of them were admitted involuntarily and therefore these drug users may tend to be more aggressive and offensive. Hence, findings from this study may not be generalizable to other clinical settings. Thirdly, another commonly used scale of psychotic symptoms, the Positive and Negative Syndrome Scale (PANSS), which is more comprehensive in assessing psychotic symptoms than BPRS \[[@R34]\], was not used in this study. We would have more findings on the symptom profile of drug users if we used PANSS in the current study. Fourth, psychiatrists who assessed the psychotic symptoms were not blinded to drug use status of subjects. Finally, our study did not collect data on the duration of psychotic symptoms, because these symptoms can be chronic, acute, or both. This is a potential confounding factor that may bias the synergistic effect of dual use of ATS and ketamine, as demonstrated in this study.

In summary, this study provides some evidence of psychotic symptomatology for the synergistic effect of dual use of ATS and ketamine. It might be due to the interactions of NMDA glutamate receptor and monoaminergic systems in the human brain. One of the potential clinical implications is that ATS and ketamine may have different effects on psychopathology. Further mechanism research is needed to clarify the interaction between amphetamine and ketamine.

MATERIALS AND METHODS {#s4}
=====================

Participants {#s4_1}
------------

Between January 2012 and December 2013, a total of 375 synthetic drug users admitted to the Drug Abuse Treatment Inpatient Ward of Wuhan Mental Health Center, were consecutively included in this study. The inclusion criteria were (1) met the criteria for "mental disorders due to psychoactive substance use/abuse" based on ICD-10 \[[@R35], [@R36]\], and (2) substances used were ATS and/or ketamine. The exclusion criteria were (1) co-occurring use of heroin, cocaine, marijuana, and other illegal substances (excluding nicotine), (2) alcohol use disorders, and (3) major medical conditions. Two licensed senior psychiatrists conducted all diagnostic assessment and clinical interviews.

According to patients' self-reported drug use patterns, we divided all patients into 2 pairs of comparison groups: ATS-only group (used ATS only) (*n* = 125) *vs*. ATS-mainly group (used ATS most of the time and ketamine sometimes, *n* = 150), and ketamine-only group (used ketamine only, *n* = 38) *vs*. ketamine-mainly group (used ATS most of the time and ketamine sometimes) (*n* = 62). This study protocol was approved by the Ethics Committee of Wuhan Mental Health Center. All participants gave written informed consent.

Demographics and drug use history {#s4_3}
---------------------------------

As a routine clinical procedure, all patients were asked to provide demographic data (gender, age, education and occupation) and urine samples for urine toxicology tests. Enzyme multiplied immunoassay technique was used in urine tests to determine the types of drugs used, including ATS, ketamine, heroin, methadone, cocaine, cannabis, and benzodiazepines. Drug use history was reported by patients, and additionally verified by urine drug test results and their family members.

Psychiatric symptom assessment {#s4_4}
------------------------------

On the day of admission, the Chinese Brief Psychiatric Rating Scale (BPRS) \[[@R37], [@R38]\] was administered to assess the psychotic and behavioral symptoms of drug users. The BPRS contains 18 items scored on a seven-point scale (1 = not present to 7 = extremely severe). The Chinese BPRS is divided into 5 subscales: anxiety/depression, anergia, thinking-disorder, activity, and hostility-suspicion. In general, BPRS total score reflects the severity of psychopathology, while its subscale scores reflect the symptoms profiles of psychotic symptoms \[[@R39]-[@R41]\]. A high score is interpreted as having severe psychotic symptoms. The Chinese BPRS has been proved to reliable and valid to assess psychotic symptoms \[[@R40], [@R42]\].

Statistical analyses {#s4_5}
--------------------

All statistical procedures were carried out by using SPSS 20.0 for Windows. Independent sample *t*-test was used to compare the symptom scores between patients used dual drugs and a single drug. Chi-square test was used to compare the group differences for category variables. The statistical significance level was set at *p* \< 0.05 (two-sided).
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